Treatment for chronic myocardial infarct

Abstract

A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).

1 . (canceled) 
     
     
         2 . A method of treating myocardial infarction comprising:
 identifying a patient with myocardial infarction with areas of myocardial infarct within the patient's myocardium; and   transendocardially injecting a therapeutic preparation comprising 30,000,000 to 264,000,000 concentrated mononuclear cells into myocardium of the patient near or in an area of infarcted tissue resulting from myocardial infarct, where said mononuclear cells were harvested from autologous bone marrow cells from the patient.   
     
     
         3 . The method of  claim 2 , wherein said at least 40% of said concentrated mononuclear cells are (a) CD-34 positive cells, (b) CD-90 positive cells, (c) CD-133 positive cells, or (d) a combination of CD-34 positive cells, CD-90 positive cells, and/or CD-133 positive cells. 
     
     
         4 . The method of  claim 2 , wherein said concentrated mononuclear cells comprises at least 40% CD-34 positive cells. 
     
     
         5 . The method of  claim 2 , wherein said concentrated mononuclear cells comprises at least 40% CD-133 positive cells. 
     
     
         6 . A method of treating myocardial infarction comprising:
 identifying a patient with myocardial infarction with areas of myocardial infarct within the patient's myocardium;   transendocardially injecting a therapeutic preparation into the myocardium of the patient near or in areas of myocardial infarct, where said therapeutic preparation comprises concentrated CD-34 positive cells and CD-133 positive cells harvested from autologous bone marrow cells of the patient and suspended in solution.   
     
     
         7 . The method of  claim 6 , wherein said at least 40% of said concentrated mononuclear cells are (a) CD-34 positive cells, (b) CD-90 positive cells, (c) CD-133 positive cells, or (d) a combination of CD-34 positive cells, CD-90 positive cells, and/or CD-133 positive cells. 
     
     
         8 . The method of  claim 6  wherein said therapeutic preparation comprising at least 40% CD-34 positive cells. 
     
     
         9 . The method of  claim 6  wherein said therapeutic preparation of the cells comprising at least 40% CD-133 positive cells. 
     
     
         10 . The method of  claim 6  wherein a concentration of mononuclear cells including CD-34 positive cells, CD-133 positive cells or a combination thereof is in the range from 10.sup.8 concentrated cells/ml of solution to 1.2.times.10.sup.8 concentrated cells/ml of solution. 
     
     
         11 . A method of treating myocardial infarction comprising:
 identifying a patient with myocardial infarction having an ejection fraction less than 40%; and transendocardially injecting a therapeutic preparation comprising concentrated CD-34 positive and CD-133 positive mononuclear cells into myocardium of the patient, where said mononuclear cells were harvested from autologous bone marrow cells from the patient.   
     
     
         12 . The method of  claim 11  wherein the therapeutic preparation comprises 30,000,000 to 264,000,000 concentrated mononuclear cells comprising CD-34 positive and CD-133 positive mononuclear cells. 
     
     
         13 . The method of  claim 11 , wherein said at least 40% of said concentrated mononuclear cells are (a) CD-34 positive cells, (b) CD-90 positive cells, (c) CD-133 positive cells, or (d) a combination of CD-34 positive cells, CD-90 positive cells, and/or CD-133 positive cells. 
     
     
         14 . The method of  claim 11  wherein said therapeutic preparation comprises at least 40% CD-34 positive cells. 
     
     
         15 . The method of  claim 11  wherein said therapeutic preparation comprises at least 40% CD-133 positive cells.